Metolazone Shortage: What Providers and Prescribers Need to Know in 2026

This guide is intended for physicians, nurse practitioners, physician assistants, and pharmacists who prescribe or manage metolazone. It provides a current clinical overview of availability, supply chain considerations, evidence-based alternative prescribing strategies, and recommendations for supporting patients who cannot access their prescribed dose.

Metolazone Supply Status as of 2026

As of 2026, metolazone (the generic successor to Zaroxolyn, Mykrox, and Diulo) is not listed on the FDA's Drug Shortage Database. This indicates that the FDA is not actively managing a national supply disruption. Multiple generic manufacturers — including Mylan, Sandoz, and Aphena — produce metolazone tablets in 2.5 mg, 5 mg, and 10 mg strengths.

However, providers should be aware that localized pharmacy-level stock-outs do occur, particularly for the 2.5 mg strength and in markets served by fewer retail pharmacy chains. Patients with heart failure who are on combination metolazone/loop diuretic therapy face the highest risk from these localized gaps, as missed doses can rapidly precipitate decompensation.

Why Metolazone Is Uniquely Difficult to Substitute

Metolazone occupies a unique pharmacological niche. Unlike standard thiazide diuretics (e.g., hydrochlorothiazide) that lose effectiveness when glomerular filtration rate (GFR) falls below 30 mL/min, metolazone retains diuretic activity even at GFR levels below 20 mL/min. This is attributed to its action on both the cortical diluting segment and the proximal convoluted tubule, and to its higher protein binding and lipid solubility compared to standard thiazides.

For patients with CKD stage 4–5 who are diuretic-resistant, metolazone is often the last oral option before escalation to IV diuresis. Substitution in this population is not straightforward.

Evidence-Based Alternative Strategies by Clinical Scenario

Scenario 1: Hypertension — Normal or Mildly Impaired Renal Function

For patients using metolazone solely for hypertension with eGFR > 30 mL/min, several substitutions are clinically reasonable:

Chlorthalidone 12.5–25 mg once daily — preferred by ACC/AHA hypertension guidelines over HCTZ; longer half-life (45–60 hours) provides smoother BP control; evidence from ALLHAT trial supports cardiovascular outcome reduction

Hydrochlorothiazide 12.5–25 mg once daily — widely available, extensively studied; note reduced efficacy at eGFR < 30

Indapamide 1.25–2.5 mg once daily — may retain antihypertensive effects in CKD; has vasodilatory properties

Scenario 2: Heart Failure Edema — Adjunct to Loop Diuretics

This is the most clinically challenging substitution scenario. Metolazone's synergistic action with loop diuretics at the distal tubule is what makes combination therapy effective in diuretic resistance. Current ACCF/AHA heart failure guidelines support metolazone as the preferred thiazide-type diuretic for augmenting loop diuretic therapy in hospitalized patients with acute decompensated heart failure.

If metolazone is temporarily unavailable for a patient in this scenario:

Consider IV loop diuretic escalation in hospitalized patients as a bridge

Chlorthalidone may be trialed in outpatients with preserved or mildly impaired renal function, though evidence for loop augmentation is less robust than for metolazone

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have a modest diuretic effect and are guideline-recommended in HFrEF — they may partially compensate but are not equivalent volume management agents

Scenario 3: CKD-Associated Edema With Severely Reduced GFR

No direct oral substitute exists for this scenario. Dose escalation of existing loop diuretics (if tolerated) or transitioning to IV diuresis may be necessary if metolazone is unavailable and the patient is symptomatic. Nephrology consultation is recommended.

Electrolyte Monitoring Considerations

Any switch or escalation in diuretic therapy warrants careful electrolyte monitoring. Key parameters to assess within 1–2 weeks of any change:

Serum potassium (risk of hypokalemia with all thiazide-type and loop diuretics)

Serum sodium (hyponatremia risk)

BUN and creatinine (renal function, risk of over-diuresis)

Serum magnesium (commonly depleted with diuretic use)

Supporting Patients Who Can't Find Metolazone

When patients report difficulty filling metolazone, consider recommending medfinder for providers. medfinder contacts pharmacies near the patient and identifies which ones have the specific metolazone strength in stock, texting results directly to the patient. This can eliminate the hours patients spend calling pharmacies and reduces the risk of missed doses due to supply gaps.

Key Clinical Takeaways for Providers

No active FDA-declared shortage as of 2026, but localized stock-outs are real and affect patient adherence

Metolazone is uniquely effective in patients with GFR < 20 mL/min — no direct oral substitute exists for this population

For hypertension patients, chlorthalidone or HCTZ are reasonable alternatives if renal function is preserved

Advise heart failure patients on combination loop diuretic + metolazone therapy to monitor weight daily and report gains exceeding 2 lb/24 hours or 5 lb/week

Mail-order pharmacy and medfinder are practical tools to prevent supply-related non-adherence

See also: How to Help Your Patients Find Metolazone In Stock: A Provider's Guide.